“…Recently, a complement inhibition therapy using eculizumab, a humanized anti-C5 monoclonal antibody, has been shown to have beneficial effects for treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in which complement-mediated damages take place [31,32]. Furthermore, it has been suggested that eculizumab might be effective in neuromyelitis optica [33], in intractable thrombotic microangiopathy associated with SLE [34] and in severe resistant LN [35].…”